Novel treatment for congenital FXIII deficiency.

University of Bern.
Blood (Impact Factor: 9.78). 05/2012; 119(22):5060-1. DOI: 10.1182/blood-2012-04-422493
Source: PubMed
  • [Show abstract] [Hide abstract]
    ABSTRACT: Coagulation factor XIII (FXIII) is best known for its role in fibrin stabilization and crosslinking of antifibrinolytic proteins to the fibrin clot. From patients with congenital FXIII deficiency it was known that FXIII also has important functions in wound healing and maintaning pregnancy. Over the last decade more and more research groups with different backgrounds have studied FXIII and have unveiled putative novel functions for FXIII. FXIII, with its unique role as a transglutaminase among the other serine protease coagulation factors, is now recognized as a multifunctional protein involved in regulatory mechanisms and construction and repair processes beyond hemostasis with possible implications in many areas of medicine. The aim of this review is to give an overview of exciting novel findings and to highlight the remarkable diversity of functions attributed to FXIII. Of course, more research into the underlying mechanisms and (patho-)physiological relevance of the many described functions of FXIII is needed. It will be exciting to observe future developments in this area and to see if and how these interesting findings may be translated into clinical practice in the future. © 2012 International Society on Thrombosis and Haemostasis.
    Journal of Thrombosis and Haemostasis 12/2012; · 6.08 Impact Factor